Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis

INTRODUCTION: Acquired resistance to endocrine therapy (ET) remains a big challenge in the management of metastatic breast cancer (MBC). A novel therapeutic agent, histone deacetylase inhibitors (HDACi), targets the abnormal epigenetic modification and may overcome acquired resistance. However, HDAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Changjun, Lin, Yan, Zhu, Hanjiang, Zhou, Yidong, Mao, Feng, Huang, Xin, Sun, Qiang, Li, Chenggang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192957/
https://www.ncbi.nlm.nih.gov/pubmed/35712478
http://dx.doi.org/10.3389/fonc.2022.901152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192957/
https://www.ncbi.nlm.nih.gov/pubmed/35712478
http://dx.doi.org/10.3389/fonc.2022.901152

Ejemplares similares